entre
ou
cadastre-se

Relevância Clínica

AC-1 AC-2 AC-3 AC-4 AC-5 AC-6 AC-7 AC-8 AC-9 AC-10 AC-11 AC-12 AC-13 AC-14 AC-15 AC-16 AC-17 AC-18 AC-19 AC-20 AC-21 AC-22 AC-23
AC-24
AC-25 AC-26 AC-27 AC-28 AC-29
BAC-1 BAC-2 BAC-3 BAC-4 BAC-5

AC-24 - Centrosome

Relevâncias Clínicas - Primeiro nível

"Within the spectrum of the SARD, the AC-24 pattern is found in patients with Raynaud’s phenomenon, localized scleroderma, SSc, SLE and RA, either alone or in combination with other SSc-associated antibodies; 102–105 "
Takahashi et al. 2016
Howng et al., 2011
Hamaguchi et al., 2015
Gavanescu et al., 1999
Antigens recognized include ?-enolase, ?-enolase, ninein, Cep-250, Mob1, PCM-1/2, pericentrin; specific immunoassays for these autoantibodies are currently not commercially available
Hamaguchi et al., 2015
Fritzler et al., 2003
Rattner et al., 1991
Mack et al., 1998
Possible association with malignancies; autoantibodies reacting with antigens in centrosomes are frequently found in sera of patients with breast cancer
Madrid et al., 2015
Maroun et al., 2014
The AC-24 pattern has low positive predictive value for any disease

Relevâncias Clínicas - Segundo nível

Possible association with infections; described in children with Mycoplasma pneumoniae infection
Cimolai, Mah & Roland, 1984
Autoantibodies to ?-enolase, ?-enolase, Mob1, PCM-1/2, and pericentrin have been described in children with cerebellar ataxia after varicella infection; one patient with hyperthyroidism and vague muscle pain and one patient with Raynaud’s phenomenon, both without evidence of a SARD, had antibodies to ?-enolase and ?-enolase
Fritzler et al., 2003
Rattner et al., 1991
With respect to autoantibodies to ninein and Cep-250, there is no apparent correlation between serum autoantibody reactivity and the clinical diagnosis; reported in RA and SLE
Mack et al., 1998
Howng et al., 2011
Most reports describe autoantibodies directly binding to specific antigens (i.e., antigen-specific immunoassays) and do not actually show correlations with the AC-24 pattern as such; specific immunoassays for these autoantibodies are currently not commercially available.